Massive Run here we come.....!!DIAGNOS' share price is poised for significant upside revaluation as its vision loss prevention Computer Assisted Retinal Analysis (CARA) business targeting diabetics is expected to show profitability this fiscal Q3 (ending December-2016) and its revenue growth curve is rapidly accelerating with no stop in sight.......https://technologymarketwatch.com/adk.htm..............